We are delighted to announce our investment in Ikarovec as part of their seed funding round. Ikarovec is a biotech gene therapy company with a focus on ophthalmology.
Norwich, UK, October 2024 – Ikarovec, which is developing novel bicistronic gene therapies for major chronic eye diseases, is pleased to announce that it has extended its seed funding round by £5M, bringing the total raised to £8M. The financing was led by existing investors LifeArc Ventures and Parkwalk Advisors, with UKI2S (managed by Future Planet Capital) also participating in the round. The company is moving towards IND-enabling studies for its lead programme, IKC159V, in geographic atrophy (GA), which causes major sight loss in millions of people globally.
The funds raised will enable the company to continue advanced preclinical studies with IKC159V, a novel bicistronic gene therapy that secretes two clinically relevant proteins that reduce overall oxidative stress and inflammation, key hallmarks of GA, in one injection. They also protect the retinal cells from atrophy and reduce the overall risk of conversion of GA to wet age-related macular degeneration. Other preclinical work and manufacturing process development will also take place with the funding.
IKC159V has shown robust and differentiated data in multiple disease relevant models, with superior efficacy to single gene therapies in comparative studies. Ikarovec has demonstrated that the gene therapy protects key retinal cells from damage whilst minimising vessel leakage and instability, processes that lead to disease progression.
Dr Katie Binley, CSO of Ikarovec, said ‘We’re excited by the progress we’ve made with our lead programme for geographic atrophy and are advancing it towards the clinic as quickly as possible. Ikarovec would like to thank its investors for their continued support to enable us to do this and to advance our pipeline of gene therapies for major eye diseases.’
Dr David Guyer, Chairman of Ikarovec, added ‘Ikarovec’s approach of expressing clinically relevant and synergistically acting proteins via bicistronic vectors differentiates it in the ophthalmic gene therapy area. The company is grateful for the ongoing recognition of its potential by LifeArc Ventures, Parkwalk Advisors and UKI2S as we develop important new products for devastating eye conditions.
In addition, the company is excited to welcome Dr Jean-Philippe Combal of Vivet Therapeutics and SpliceBio to the Board as a Non-Executive Director. He brings extensive experience in both ophthalmic product development and gene therapy through positions at GenSight Biologics and Sanofi-Fovea.’
For more on Ikarovec, visit their website or our portfolio page.
